Nectar Lifesciences Limited has informed the Exchange about Revised legible Copy of Newspaper Publication
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences has submitted a revised legible copy of the newspaper advertisement containing its unaudited financial results for the quarter ended June 30, 2025, published in 'Desh Sewak' (Punjabi) on August 15, 2025, in the language of the region where its registered office is located. The embedded results show revenue from operations of Rs 34,026.05 lakh in Q1 FY26, down from Rs 41,796.11 lakh in Q1 FY25 (an ~18.6% YoY decline). The company swung to a loss before tax of Rs 9,675.43 lakh versus a profit of Rs 491.71 lakh in the year-ago quarter, and reported a net loss of Rs 6,323.06 lakh (vs. a net profit of Rs 296.91 lakh last year). EPS turned negative at Rs (2.82) compared to Rs 0.13 in Q1 FY25. The filing itself is a procedural re-submission of a clearer copy of the same results already published.
The filing carries no new information beyond what was already disclosed, but the underlying results are weak — sharp revenue drop and a swing into losses may weigh on the stock. Investors should track management commentary on the cause of the YoY deterioration.